Health Condition 1: L400- Psoriasis vulgaris
Conditions
Interventions
Intervention1: Tab Methotrexate 7.5mg weekly in 3 equally divided doses of 2.5mg.: Tab Methotrexate 7.5mg weekly in 3 equally divided doses given as follows :-
1)Tab Methotrexate 2.5mg Twice a day (on
Sponsors
Trish Larissa Miranda
Eligibility
Inclusion criteria
Inclusion criteria: 1)Male and female patients above 18 years with plaque psoriasis. 2)Involvement of 20% or more of body surface area with plaque psoriasis.
Exclusion criteria
Exclusion criteria: 1)Pregnancy 2)Lactating women. 3)Immunosuppressed individuals 4)Patients with pustular psoriasis. 5)Patients with erythrodermic psoriasis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name-Psoriasis Area Severity Index(PASI) based on the following parameters:- 1. Erythema 2. Induration 3. Desquamation or scaling Timepoint: Week 0-Baseline Week 4 Week 8 Week 12 Week 16 | — |
Secondary
| Measure | Time frame |
|---|---|
| PASI-75-To compare the efficacy of Methotrexate and Apremilast by comparing their PASI-75 scores that is time taken for 75% or more reduction of psoriasis lesions from baseline lesions.Timepoint: Not fixed,depending on the time taken to show 75% or more improvement from baseline lesions for each of the 2 drugs separately. | — |
Countries
India
Contacts
Public ContactTrish Larissa Miranda
Mahatma Gandhi Mission Medical College and Hospital,Aurangabad
Outcome results
None listed